Literature DB >> 29556310

MAP30 promotes apoptosis of U251 and U87 cells by suppressing the LGR5 and Wnt/β-catenin signaling pathway, and enhancing Smac expression.

Yilin Jiang1, Junjie Miao1, Dongliang Wang1, Jingru Zhou1, Bo Liu1, Feng Jiao1, Jiangfeng Liang2, Yangshuo Wang1, Cungang Fan1, Qingjun Zhang1.   

Abstract

Significant antitumor activity of Momordica anti-human immunodeficiency virus protein of 30 kDa (MAP30) purified from Momordica charantia has been the subject of previous research. However, the effective mechanism of MAP30 on malignant glioma cells has not yet been clarified. The aim of the present study was to investigate the effects and mechanism of MAP30 on U87 and U251 cell lines. A Cell Counting Kit-8 assay, wound healing assay and Transwell assay were used to detect the effects on U87 and U251 cells treated with different concentrations of MAP30 (0.5, 1, 2, 4, 8 and 16 µM) over different periods of time. Proliferation, migration and invasion of each cell line were markedly inhibited by MAP30 in a dose- and time-dependent manner. Flow cytometry and fluorescence staining demonstrated that apoptosis increased and the cell cycle was arrested in S-phase in the two investigated cell lines following MAP30 treatment. Western blot analysis demonstrated that leucine-rich-repeat-containing G-protein-coupled receptor 5 (LGR5) expression and key proteins in the Wnt/β-catenin signaling pathway were apparently decreased, whereas second mitochondria-derived activator of caspase (Smac) protein expression significantly increased with MAP30 treatment in the same manner. These results suggest that MAP30 markedly induces apoptosis in U87 and U251 cell lines by suppressing LGR5 and the Wnt/β-catenin signaling pathway, and enhancing Smac expression in a dose- and time-dependent manner.

Entities:  

Keywords:  Momordica charantia anti-human immunodeficiency virus protein 30; Wnt/β-catenin signaling; apoptosis; glioma; leucine-rich-repeat-containing G-protein-coupled receptor 5; second mitochondria-derived activator of caspase

Year:  2018        PMID: 29556310      PMCID: PMC5844066          DOI: 10.3892/ol.2018.8073

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  46 in total

1.  Momordica Charantia lectin, a type II ribosome inactivating protein, exhibits antitumor activity toward human nasopharyngeal carcinoma cells in vitro and in vivo.

Authors:  Evandro Fei Fang; Chris Zhi Yi Zhang; Tzi Bun Ng; Jack Ho Wong; Wen Liang Pan; Xiu Juan Ye; Yau Sang Chan; Wing Ping Fong
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-20

2.  Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis.

Authors:  Ratna B Ray; Amit Raychoudhuri; Robert Steele; Pratibha Nerurkar
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

3.  Effects of recombinant MAP30 on cell proliferation and apoptosis of human colorectal carcinoma LoVo cells.

Authors:  Jian-Ming Fan; Jun Luo; Jun Xu; Sha Zhu; Qiao Zhang; De-Fu Gao; Yu-Bao Xu; Gai-Ping Zhang
Journal:  Mol Biotechnol       Date:  2008-02-01       Impact factor: 2.695

4.  Origin of the U87MG glioma cell line: Good news and bad news.

Authors:  Marie Allen; Mia Bjerke; Hanna Edlund; Sven Nelander; Bengt Westermark
Journal:  Sci Transl Med       Date:  2016-08-31       Impact factor: 17.956

5.  The nitric oxide donor JS-K sensitizes U87 glioma cells to repetitive irradiation.

Authors:  Max Heckler; Nadja Osterberg; Jessica Guenzle; Nina Kristin Thiede-Stan; Wilfried Reichardt; Claudia Weidensteiner; Joseph E Saavedra; Astrid Weyerbrock
Journal:  Tumour Biol       Date:  2017-06

6.  The antiviral agents, MAP30 and GAP31, are not toxic to human spermatozoa and may be useful in preventing the sexual transmission of human immunodeficiency virus type 1.

Authors:  C A Schreiber; L Wan; Y Sun; L Lu; L C Krey; S Lee-Huang
Journal:  Fertil Steril       Date:  1999-10       Impact factor: 7.329

7.  Myc down-regulation affects cyclin D1/cdk4 activity and induces apoptosis via Smac/Diablo pathway in an astrocytoma cell line.

Authors:  D Amendola; M De Salvo; R Marchese; C Verga Falzacappa; A Stigliano; E Carico; E Brunetti; M Moscarini; B Bucci
Journal:  Cell Prolif       Date:  2009-02       Impact factor: 6.831

8.  Knockdown of LGR5 suppresses the proliferation of glioma cells in vitro and in vivo.

Authors:  Dongliang Wang; Jingru Zhou; Cungang Fan; Feng Jiao; Bo Liu; Peng Sun; Junjie Miao; Qingjun Zhang
Journal:  Oncol Rep       Date:  2013-10-31       Impact factor: 3.906

9.  Mono-PEGylation of Alpha-MMC and MAP30 from Momordica charantia L.: Production, Identification and Anti-Tumor Activity.

Authors:  Yun Sun; Fenghui Sun; Jianlong Li; Minlu Wu; Xiang Fan; Yanfa Meng; Yao Meng
Journal:  Molecules       Date:  2016-10-31       Impact factor: 4.411

10.  A novel method for simultaneous production of two ribosome-inactivating proteins, α-MMC and MAP30, from Momordica charantia L.

Authors:  Yao Meng; Sen Lin; Shuangfeng Liu; Xiang Fan; Gangrui Li; Yanfa Meng
Journal:  PLoS One       Date:  2014-07-08       Impact factor: 3.240

View more
  4 in total

1.  Inhibitory effects of miR‑26b‑5p on thyroid cancer.

Authors:  Aiya Zhou; Gengyu Chen; Xiankui Cheng; Chi Zhang; Hao Xu; Ming Qi; Xiao Chen; Tiantian Wang; Leping Li
Journal:  Mol Med Rep       Date:  2019-05-31       Impact factor: 2.952

2.  Chidamide Inhibits Glioma Cells by Increasing Oxidative Stress via the miRNA-338-5p Regulation of Hedgehog Signaling.

Authors:  Haixia Zhou; Liang Han; Han Wang; Jun Wei; Zhigang Guo; Zhaohui Li
Journal:  Oxid Med Cell Longev       Date:  2020-03-11       Impact factor: 6.543

Review 3.  Bitter Melon (Momordica Charantia), a Nutraceutical Approach for Cancer Prevention and Therapy.

Authors:  Subhayan Sur; Ratna B Ray
Journal:  Cancers (Basel)       Date:  2020-07-27       Impact factor: 6.639

4.  Imaging the transmembrane and transendothelial sodium gradients in gliomas.

Authors:  Muhammad H Khan; John J Walsh; Jelena M Mihailović; Sandeep K Mishra; Daniel Coman; Fahmeed Hyder
Journal:  Sci Rep       Date:  2021-03-23       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.